Roman seems a typical six-year-old boy, smiling shyly next to his younger sister and mother, Silvia, as they open the door to their Amsterdam home.
However, Roman has Duchenne muscular dystrophy (DMD), a genetic disorder that already makes it hard to walk long distances and will probably put him in a wheelchair by his teens. Lung and heart problems mean most DMD patients die aged 25 to 30 years.
“He knows that his muscles are not that strong, but he does not know it is progressive,” Dutch events manager Silvia says. “He will ask about it himself, when he can handle it. That’s the hard thing, his pain — that’s the hardest thing.”
Photo: REUTERS
Yet there is a glimmer of hope. Roman’s mother believes a small Dutch biotech company called Prosensa, located 40km away in the university town of Leiden, may finally have found a way to help Roman and others like him.
She’s not the only excited one. GlaxoSmithKline is throwing its weight behind the new drug and the two companies last month started a final-stage Phase III clinical study of a product that might help up to 13 percent of boys with DMD.
Silvia hopes Roman will be enrolled in subsequent trials.
Prosensa is one of a new wave of successful European biotechs, many of them in the Benelux countries and Scandinavia. They are stepping over a past generation of biotech failures and starting to win interest from investors.
Significantly, it focuses on rare diseases — a red-hot area in the wake of Sanofi-Aventis’s US$20 billion-plus deal to buy Genzyme.
Europe’s biotech sector has stumbled in the past, but there is now renewed talk of stock market listings and trade sales.
Prosensa is preparing the ground for an initial public offering (IPO) and will choose its moment carefully.
“It is one of the options,” chief executive Hans Schikan said.
Prosensa last year hired a chief financial officer with IPO experience, although chief business officer Luc Dochez stresses a flotation “will be a choice, not a forced option” as Prosensa still has two years of funding.
Other young biotech companies are also eyeing the public markets, including Dutch rival Kiadis, a specialist in cell-based therapy, which bankers believe is again looking to list after pulling a planned IPO in 2007.
There are signs the market is recovering from recent trough years and this year could see more IPOs, with investor interest in places like Amsterdam and Brussels encouraging, although the overall picture is fragile.
“The market is improving. In Europe, a few biotech IPOs are being planned,” one banker said.
The Netherlands and Belgium are a hotspot, helped by the sentiment-boosting US$2.4 billion buyout of Dutch vaccine maker Crucell by Johnson & Johnson and high hopes for Belgian biotech star performer ThromboGenics. Some German and Austrian IPOs are also on the cards, bankers say.
BRITISH BLUES
Nomura analyst Samir Devani detects a “power shift” in European biotech, particularly away from the UK, where a series of blow-ups with key pipeline products at companies like Antisoma have taken a heavy toll on confidence.
Last year saw the emergence of a new group of well-financed European biotechs worth US$500 million or more, including ThromboGenics, Sweden’s Medivir, Denmark’s Bavarian Nordic, Sweden’s Diamyd Medical and Norway’s Algeta, he said.
The biotech casino remains high-risk, given the binary nature of the clinical trials that drive values. However, the growing appetite of “Big Pharma” for biotech assets is underpinning the sector and analysts at Jefferies expect out-licensing deals and consolidation to remain key share price drivers this year.
For those companies braving the IPO market, however, the waters are still choppy.
Danish biotech Zealand Pharma, for example, got its issue away in November, but only after pricing it at the low end of the indicated range. The shares have fallen more than 20 percent since then.
More recently, Swiss-Italian biotech Philogen scrapped its plans to list in Milan after Bayer ended a partnership with the group.
Despite the setbacks, Thomson Reuters data shows an overall pick-up in biotech IPOs last year after a dramatic slowdown in 2008 and 2009.
US biotech have also had mixed results this year, with Pacira Pharmaceuticals and Endocyte Inc going public, but Clarus Therapeutics pulling its IPO on Feb. 11.
Anne Portwich, a partner at Life Sciences Partners, said many venture capitalists looking to realize biotech investment gains were now more focused on M&A than IPOs.
“Companies that want an IPO have to be much more mature than they did in the past,” she said.
BENELUX VS SWITZERLAND
After various high-profile setbacks, times are tough in Switzerland. Historically a center of excellence, the talk these days among biotech executives is of survival.
Sander Slootweg, managing partner at venture capital firm Forbion, said that in the past, some over-priced Swiss biotechs had raised cash at “valuations that we would never invest in.”
Tim Dyer, chief financial officer of Swiss biotech Addex, said a shortage of capital may mean some companies either have to close or merge to create critical mass.
“One of the strategies of these sub-SF$100 million [US$107.7 million] market cap biotechs could be to combine with other similarly sized companies to recreate the critical mass and put themselves back on the radar screen of larger funds,” Dyer said.
Vontobel analyst Andrew Weiss agreed a wave of M&A could be brewing as a last resort for some companies.
For different reasons, he said Cytos Biotechnology, Cosmo Pharmaceuticals, Evolva and also Addex could also look to team up, but not necessarily with each other.
Back in Belgium, Edwin Moses, the CEO of biotech Ablynx, which makes drugs based on llama DNA, finds the investor mood rather different — helped by a strong retail interest that runs beyond the -traditional wary Belgian dentist.
“I’ve found that people in the street, bakers and taxi drivers, they all follow companies like Ablynx, like ThromboGenics, very carefully in a way that I’ve not experienced in the larger countries,” Moses said.
“There’s quite a sophisticated retail market here where people pay attention even to complicated stories,” he said. “At the moment the place to be seems to be here.”
Whether the science will help boys like Roman remains to be seen. Prosensa and Glaxo are still recruiting the 180 patients they need for their key Phase III study and it will take 48 weeks of regular injections to determine if they really do have the first treatment to alter the course of DMD.
“Hope gives life,” said Roman’s mother, Silvia.
China has claimed a breakthrough in developing homegrown chipmaking equipment, an important step in overcoming US sanctions designed to thwart Beijing’s semiconductor goals. State-linked organizations are advised to use a new laser-based immersion lithography machine with a resolution of 65 nanometers or better, the Chinese Ministry of Industry and Information Technology (MIIT) said in an announcement this month. Although the note does not specify the supplier, the spec marks a significant step up from the previous most advanced indigenous equipment — developed by Shanghai Micro Electronics Equipment Group Co (SMEE, 上海微電子) — which stood at about 90 nanometers. MIIT’s claimed advances last
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) has appointed Rose Castanares, executive vice president of TSMC Arizona, as president of the subsidiary, which is responsible for carrying out massive investments by the Taiwanese tech giant in the US state, the company said in a statement yesterday. Castanares will succeed Brian Harrison as president of the Arizona subsidiary on Oct. 1 after the incumbent president steps down from the position with a transfer to the Arizona CEO office to serve as an advisor to TSMC Arizona’s chairman, the statement said. According to TSMC, Harrison is scheduled to retire on Dec. 31. Castanares joined TSMC in
EUROPE ON HOLD: Among a flurry of announcements, Intel said it would postpone new factories in Germany and Poland, but remains committed to its US expansion Intel Corp chief executive officer Pat Gelsinger has landed Amazon.com Inc’s Amazon Web Services (AWS) as a customer for the company’s manufacturing business, potentially bringing work to new plants under construction in the US and boosting his efforts to turn around the embattled chipmaker. Intel and AWS are to coinvest in a custom semiconductor for artificial intelligence computing — what is known as a fabric chip — in a “multiyear, multibillion-dollar framework,” Intel said in a statement on Monday. The work would rely on Intel’s 18A process, an advanced chipmaking technology. Intel shares rose more than 8 percent in late trading after the
FACTORY SHIFT: While Taiwan produces most of the world’s AI servers, firms are under pressure to move manufacturing amid geopolitical tensions Lenovo Group Ltd (聯想) started building artificial intelligence (AI) servers in India’s south, the latest boon for the rapidly growing country’s push to become a high-tech powerhouse. The company yesterday said it has started making the large, powerful computers in Pondicherry, southeastern India, moving beyond products such as laptops and smartphones. The Chinese company would also build out its facilities in the Bangalore region, including a research lab with a focus on AI. Lenovo’s plans mark another win for Indian Prime Minister Narendra Modi, who tries to attract more technology investment into the country. While India’s tense relationship with China has suffered setbacks